Government seeks industry-led reforms, stronger research and global regulatory compliance to transform pharmaceuticals into a major export engine.
Federal Minister for Planning, Development and Special Initiatives Professor Ahsan Iqbal has urged Pakistan’s pharmaceutical industry to prepare a comprehensive strategy aimed at transforming the sector into a globally competitive and innovation-focused export hub.
Chairing a roundtable with representatives of the pharmaceutical industry on Friday, the minister called for a month-long consultation involving industry stakeholders, universities and research organisations.
The exercise will identify key challenges, reforms and government support required to develop a roadmap extending to 2030 and beyond.
Ahsan Iqbal highlighted the sector’s record performance in fiscal year 2025, when pharmaceutical exports reached $457 million, the highest level recorded in two decades.
He said the industry should build on this progress and contribute to Pakistan’s broader goal of exceeding $100 billion in annual exports by 2035.
The pharmaceutical industry currently comprises 662 manufacturers and generated Rs523 billion in revenue during FY2025, reflecting 19.4% growth.
Under the proposed export roadmap, the sector aims to reach $2 billion in exports before expanding to $3 billion through PharmEx within three years and ultimately achieving $10 billion within eight years.
The minister stressed that international quality standards and regulatory compliance would be critical for achieving these targets.
Pakistan currently has access to 52 WHO Level 2 markets, while achieving WHO Level 3 status by April 2027 could potentially expand access to more than 150 international markets.
He also called for greater diversification of export destinations and regulatory reforms that would allow more Pakistani pharmaceutical companies and products to enter advanced global markets.
Reducing dependence on imported raw materials was another key priority. Ahsan noted that nearly 85% of active pharmaceutical ingredients are imported, with China accounting for approximately 85-90% of those supplies.
He urged greater domestic investment in technology, research, innovation and higher-value manufacturing.
The minister further stressed stronger cooperation between universities, pharmacy departments, research institutions and pharmaceutical companies. He said research and laboratory investments should lead to commercially viable products and technologies.
Ahsan directed stakeholders to submit measurable targets, priority reforms and practical recommendations. He assured the industry of government support in removing administrative and regulatory barriers and creating a stable environment for expansion.
The consultation is part of a Planning Commission initiative focused on strengthening Pakistan’s high-value export sectors and developing internationally competitive industrial clusters.